lung cancer
Conditions
Interventions
Observation group:None
Sponsors
Shaoxing People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged between 18 and 75 years (inclusive); 2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC (all histological types); 3. Detection confirmed EGFR mutations (including 19del and 21 L858R, excluding 20 exon insertions), accepting pathological examination results from other hospitals; 4. After first-line monotherapy with third-generation EGFR-TKIs (allowing less than two cycles of chemotherapy in between treatments), if slow progression occurs, and the investigator assesses that continuing with the original third-generation EGFR-TKIs still provides benefit (original TKI dosage unchanged); Note: Patients who have had disease control for >=3 months after treatment with third-generation EGFR-TKIs and clinically show slow progression. Specifically defined as: a slight increase in tumor harm to the body compared to previous assessments (no worsening of symptoms); progression of non-target lesions, such as pleural effusion, or a total of up to 5 combined extra-cranial/intracranial progresses (local treatment methods can be used simultaneously/sequentially); 5. At least one measurable target lesion present in the last 3 months (according to RECIST version 1.1 standards); 6. ECOG score: 0-2.
Exclusion criteria
Exclusion criteria: 1. Small cell lung cancer (including mixed small cell lung cancer and non-small cell lung cancer); 2. Patients with primary resistance to third-generation EGFR-TKIs therapy (treatment duration = 2.4 months, rapid deterioration of clinical symptoms, significant progression of target lesions compared to the previous evaluation, and worsening symptoms); 4. Patients who underwent synchronous or sequential use of other systemic therapies after slow progression, such as chemotherapy, bevacizumab, etc.; 5. Patients who, as determined by the investigator, switched to other chemotherapy or targeted drugs after progression.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Imaging materials; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor index test; | — |
Countries
China
Contacts
Public ContactGuangmao Yu
Shaoxing People's Hospital
Outcome results
None listed